Ask AI
IMforte
IMforte: Phase III Trial of Lurbinectedin + Atezolizumab vs Atezolizumab as First-line Maintenance Therapy in ES-SCLC

Released: June 05, 2025

Expiration: December 04, 2025

Activity

Progress
1
Course Completed
Activity Information

Released: June 05, 2025

Expiration: December 04, 2025